May. 4 at 2:47 PM
$MIST - Analyst Outlook: The Wall Street consensus remains a Moderate to Strong Buy, with an average price target hovering between
$6.73 and
$7.50. Most analysts view the stock as highly undervalued at its current trading levels (around
$1.82–
$1.87), noting that the market may not yet be pricing in the long-term potential of the PSVT indication or the ongoing Phase 3 trials for atrial fibrillation with rapid ventricular rate (AFib-RVR).
$BMY $ABT $JNJ
